- Home
- FBIO vs ICCC Comparison
FBIO vs ICCC Comparison
Compare FBIO & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIO
- ICCC
- Stock Information
- Founded
- FBIO 2006
- ICCC 1982
- Country
- FBIO United States
- ICCC United States
- Employees
- FBIO N/A
- ICCC N/A
- Industry
- FBIO Biotechnology: Pharmaceutical Preparations
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- FBIO Health Care
- ICCC Health Care
- Exchange
- FBIO Nasdaq
- ICCC Nasdaq
- Market Cap
- FBIO 49.1M
- ICCC 48.3M
- IPO Year
- FBIO N/A
- ICCC 1987
- Fundamental
- Price
- FBIO $1.69
- ICCC $5.07
- Analyst Decision
- FBIO Strong Buy
- ICCC
- Analyst Count
- FBIO 3
- ICCC 0
- Target Price
- FBIO $21.00
- ICCC N/A
- AVG Volume (30 Days)
- FBIO 144.5K
- ICCC 27.6K
- Earning Date
- FBIO 05-19-2025
- ICCC 05-14-2025
- Dividend Yield
- FBIO N/A
- ICCC N/A
- EPS Growth
- FBIO N/A
- ICCC N/A
- EPS
- FBIO N/A
- ICCC N/A
- Revenue
- FBIO $57,675,000.00
- ICCC $26,493,169.00
- Revenue This Year
- FBIO $63.20
- ICCC N/A
- Revenue Next Year
- FBIO $66.70
- ICCC N/A
- P/E Ratio
- FBIO N/A
- ICCC N/A
- Revenue Growth
- FBIO N/A
- ICCC 51.63
- 52 Week Low
- FBIO $1.33
- ICCC $3.34
- 52 Week High
- FBIO $2.89
- ICCC $5.82
- Technical
- Relative Strength Index (RSI)
- FBIO 52.97
- ICCC 42.10
- Support Level
- FBIO $1.67
- ICCC $5.01
- Resistance Level
- FBIO $1.84
- ICCC $5.72
- Average True Range (ATR)
- FBIO 0.09
- ICCC 0.18
- MACD
- FBIO 0.01
- ICCC -0.05
- Stochastic Oscillator
- FBIO 58.54
- ICCC 14.96
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.